Osteocalcin, cortisol levels, and bone mineral density in prepubertal children with asthma treated with long-term fluticasone propionate.

Creative Commons License

Ozkaya E., NURSOY M. A., Uzuner S., Erenberk U., Cakir E.

Hormone research in paediatrics, vol.77, no.6, pp.351-7, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 77 Issue: 6
  • Publication Date: 2012
  • Doi Number: 10.1159/000338785
  • Journal Name: Hormone research in paediatrics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.351-7
  • Bezmialem Vakıf University Affiliated: Yes


Aims: The objective of this study is to determine the effects of the long-term treatment with inhaled fluticasone propionate on osteocalcin, cortisol levels, and bone mineral status in children with asthma. Methods: This cross-sectional study examined 230 prepubertal children with asthma (aged 6-11) who had intermittently used inhaled fluticasone propionate for at least 5 years at a mean daily dose of 200 mu g (range: 200-350 mu g). Serum osteocalcin, cortisol, and bone mineral density (BMD) of the lumbar spine were obtained from each participant. The control group consisted of gender-and age-matched children (n = 170) who were newly diagnosed with asthma and who were not being treated with corticosteroid. Results: The average age (+/- SEM) was 8.9 +/- 0.7 years, their mean (+/- SEM) daily steroid dose was 180.3 +/- 55.0 mu g, with 236.5 +/- 17.2 g total steroid use during treatment. Between the study and the control groups, no significant differences were observed in cortisol, osteocalcin levels, and BMD (p > 0.05). Conclusion: Long-term treatment with inhaled fluticasone propionate (100 mu g twice daily) revealed no negative effects on serum osteocalcin, cortisol levels, and BMD in children with asthma. Copyright (C) 2012 S. Karger AG, Basel